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Introduction
Th   e potential use of embryonic stem cells (ESCs) for cell 
replacement therapies is limited by ethical concerns and 
the technical hurdles associated with their isolation from 
human embryos. In addition, as the genetic identity of 
the donor egg from which the ESCs are derived most 
likely will diﬀ  er from that of potential recipients, patients 
who receive ESC-derived cells or tissues may face the 
same complications that result from organ trans  plan-
tation (for example, immunorejection, graft-versus-host 
disease, and need for immunosuppression). To circum-
vent these obstacles, considerable eﬀ   ort has been 
invested in attempting to derive ESC-like cells by 
reprogramming somatic cells to an embryonic state. 
Although exciting results have been achieved by means 
of somatic cell nuclear transfer, cell fusion, and culture-
induced reprogramming [1], these procedures are tech-
nically demanding and ineﬃ   cient and therefore unlikely 
to become a common approach for producing patient-
speciﬁ  c pluripotent cells. In 2006, a major breakthrough 
was reported in Japan by Takahashi and Yamanaka, who 
described the generation of induced pluripotent stem 
cells (iPSCs) from mouse ﬁ  broblasts via overexpression 
of deﬁ  ned transcription factors [2]. Shortly afterwards, 
the original experimental protocol was replicated and 
optimized by several laboratories, conﬁ  rming that iPSCs 
share the gene expression proﬁ   le, epigenetic modiﬁ  -
cations, and prolifera  tion rates as well as the pluripotency 
of ESCs [3]. Importantly, iPSCs were subsequently derived 
from adult human ﬁ  broblasts, providing a feasible way of 
producing tailor-made pluripotent cells with clinical 
translational potential [4-7].
Th  e fact that iPSCs can be derived from easily 
accessible somatic cells, such as skin ﬁ  broblasts  or 
keratino  cytes [8], has opened up new horizons in the 
ﬁ  eld of regenerative medicine [9]. Jaenisch and colleagues 
[10,11] showed – as proof of principle of the therapeutic 
potential of iPSCs – the rescue of sickle cell disease and 
Parkinson disease in mouse models after transplantation 
of iPSC-derived hematopoietic stem cells and dopa-
minergic neurons, respectively. Similarly, correction of a 
mouse model of hemophilia A was recently demonstrated 
by intra-liver injection of endothelial cells and endothelial 
progenitor cells diﬀ  erentiated from iPSCs [12]. On the 
basis of the unlimited capacity to be propagated in vitro, 
iPSCs are good targets for genetic manipulation by gene 
therapy or gene correction by homologous recombina-
tion. Ideally, iPSC-based therapies in the future will rely 
on the isolation of skin ﬁ  broblasts or keratinocytes, their 
reprogramming into iPSCs, and the correction of the 
genetic defect followed by diﬀ  erentiation into the desired 
cell type and transplantation. Although this technology 
holds the potential to revolutionize drug discovery and 
regenera  tive medicine, important technical issues asso-
ciated with the derivation of iPSCs still hinder its clinical 
translation. In this review, we outline current repro-
gramming approaches developed to improve the safety 
and eﬃ   ciency of the method and highlight its critical 
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iPSCs.
Delivery of reprogramming factors by integrating 
viral vectors
Several experimental strategies have been developed to 
derive iPSCs from diﬀ   erentiated somatic cells (sum-
marized in Figure 1). Direct reprogramming was originally 
achieved by retroviral transduction of trans  cription 
factors. Retroviruses are highly eﬃ   cient  gene-transfer 
vehicles because they provide prolonged expres  sion of the 
transgene after genomic integration and have low 
immuno  genicity. Most replication-defective retro  viral 
vectors derive from the Moloney murine leukemia virus by 
replacing the viral structural genes (gag, pol, and env) with 
the gene of interest while retaining the cis-acting 
sequences. Th  ese include the 5΄ and 3΄ long terminal 
repeats (LTRs), a packaging signal, and elements involved 
in reverse transcription and chromosomal integration. To 
produce recombinant retroviruses, the plasmid is intro-
duced into a packaging cell line that provides the viral 
proteins in trans. Using four individual retroviruses encod-
ing the transcription factors Oct4, Klf4, Sox2, and c-Myc, 
Takahashi and Yamanaka [2] were able to obtain pluri-
potent cells by selecting for Fbx15 expression in ESC 
culture conditions. Fbx15, though an ESC marker, is not 
essential for the maintenance of the pluripotent state, 
and this, together with the timing of drug selection, may 
explain why the ﬁ  rst iPSC lines failed to generate adult 
chimeric mice and exhibited a global gene-expression 
proﬁ  le that was similar but not identical to that of ESCs. 
Further studies showed that delayed selection for the 
expression of key regulators of pluri  potency such as Oct4 
or Nanog yielded germline-competent iPSCs [13-15]. 
Importantly, fully reprogrammed clones could also be 
derived from genetically unmodiﬁ  ed cells by means of 
colony morphology-based selection [16], thus enabling 
many laboratories to use the tech  nique without requiring 
speciﬁ   c cell lines. Shortly after the original report by 
Takahashi and Yamanaka, their group [5] and teams led by 
James Th   omson [6] in Wisconsin and George Daley [4] in 
Boston were able to produce iPSCs from human ﬁ  broblasts 
by using a similar experimental design. In all cases, the 
resulting human iPSCs (hiPSCs) were remarkably similar 
to human ESCs in terms of morpho  logy, surface marker 
expression, methy  lation status in the promoter regions of 
pluri potency-associated  genes,  in vitro diﬀ  erentiation, and 
teratoma formation. After these ﬁ  rst studies, retroviruses 
were used to reprogram somatic cells from patients with a 
variety of diseases, including amyotrophic lateral sclerosis, 
Parkinson disease, type 1 diabetes mellitus, Huntington 
disease, and Down syndrome [17,18], providing an 
unprecedented oppor  tunity for disease modeling and drug 
screening.
Delivery of reprogramming factors via lentiviral vectors 
was ﬁ  rst reported by the Th   omson lab [6] and later was 
successfully employed to generate hiPSCs from various 
cell types, including skin ﬁ  broblasts, keratinocytes [19], 
and adipose stem cells [20]. Lentiviruses are a subclass of 
retroviruses capable of transducing a wide range of both 
dividing and non-dividing cells. Lentiviral insertion sites 
are often found anywhere within the transcriptional unit, 
whereas gamma-retroviruses tend to integrate near 
transcriptional start sites [21]. Another major diﬀ  erence 
between retroviral and lentiviral vectors is the degree of 
silencing to which they are subject in pluripotent cells. 
For retroviruses, silencing is almost complete and 
provides a way to identify fully reprogrammed clones 
[22] but also decreases the eﬃ     ciency of the process. 
Lentiviruses seem to escape silencing to varying degrees, 
depending in part on the species and the promoter 
sequence. Moreover, position eﬀ  ects are often associated 
with variegated expression of the transgene. Even with 
doxicycline-inducible systems, low levels of transgene 
expression have been found to aﬀ  ect the transcriptome of 
iPSCs [23]. Th   is adverse eﬀ  ect is more pronounced with 
constitutive promoters like human EF1α (elongation 
factor-1 alpha), whose activity in the context of repro-
gramming results in continued transgene expression that 
severely impairs diﬀ  erentiation both in vivo and in vitro 
[24]. Th   e lack of silencing of lentiviral vectors increases 
the eﬃ   ciency of iPSC generation, but transgene excision 
may be required to generate fully functional pluripotent 
cells [24].
Excisable vectors for the production of transgene-
free induced pluripotent stem cells
Despite the fact that viral vectors have proven to be 
eﬀ   ective tools for reprogramming, the resulting iPSC 
clones usually display several proviral integrations, 
ultimately increasing the risk of insertional mutagenesis. 
In addition, spontaneous transgene reactivation may 
occur and lead to tumor formation [13]. Furthermore, we 
have shown that residual transgene expression aﬀ  ects the 
developmental potential of iPSCs [24]. Th  ese ﬁ  ndings 
have encouraged researchers to look for alternative gene-
delivery methods to generate transgene-free iPSCs that 
are suitable for basic research and clinical applications.
A feasible way to decrease the risk of insertional muta-
genesis is to combine the reprogramming factors into a 
single polycistronic vector by inserting a ‘self-cleaving’ 
2A peptide or an internal ribosome entry site (IRES) 
sequence between two consecutive open reading frames. 
With this approach, expression of the four factors can be 
accomplished in virtually every transduced cell, with a 
consequent increase in the reprogramming eﬃ   ciency. A 
number of studies have recently demonstrated the 
advantage of using polycistronic vectors for iPSC 
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adult mouse ﬁ   broblasts to iPSCs (0.5% to 1% of 
transduced cells) by using either a constitutive or an 
inducible version of the Stem Cell Cassette (STEMCCA) 
polycis  tronic lentiviral vector [25]. In this vector, a 
combination of 2A peptides with an IRES sequence 
allowed the appropriate expression of the four 
reprogramming factors. Similarly, the Jaenisch group [26] 
developed a single polycistronic Dox-inducible lentiviral 
vector encoding the four factors separated by three 
diﬀ  erent 2A peptides and demonstrated successful repro-
gramming of mouse ﬁ   broblasts and neonatal human 
foreskin keratino  cytes with 0.0001% and 0.00001% 
eﬃ   ciencies, respec  tively. Notably, these studies demon-
strated that somatic cells carrying a single proviral copy 
of the polycistronic cassette can be reprogrammed to 
pluripotency, sub  stantially reducing genomic modiﬁ  cation 
of the target cell.
Th  e possibility of deriving iPSCs with single proviral 
integrations has stimulated the development of method-
olo  gies aimed at removing the transgenes by Cre/loxP 
technology. To this end, a loxP site is inserted into the 3΄ 
LTR region of the lentiviral vector. During the normal 
reverse transcription cycle of the virus before integration, 
the loxP sequence is duplicated into the 5΄ LTR region, 
creating a loxP-ﬂ  anked or ‘ﬂ  oxed’ version of the vector 
that integrates into the host chromosome. After repro-
gramming, transgene-free iPSCs can be obtained by 
treatment with Cre recombinase and selection of clones 
that have undergone excision. Soldner and colleagues 
[23] performed excision of multiple integrated lentiviral 
vectors in hiPSCs by transfecting the cells with a plasmid 
Figure 1. Overview of reprogramming methodologies. *Overall comparable effi   ciency. #Reprogramming using only small molecules has not 
been reported yet. 5΄-azaC, 5΄-azacytidine; iPSC, induced pluripotent stem cell; LTR, long terminal repeat; TGF-β, transforming growth factor-beta; 
VPA, valproic acid.
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selection of resistant clones. Similarly, a Cre-expressing 
plasmid or adenovirus was employed to remove three or 
four copies of a polycistronic vector from the genome of 
mouse iPSCs [27]. Moving the technology a step forward, 
we accomplished highly eﬃ   cient removal of a single copy 
of the ‘ﬂ  oxed’ STEMCCA vector in mouse iPSCs through 
adenoviral-mediated expression of Cre in the absence of 
selection [24]. Likewise, eﬃ     cient excision of a single 
integrated human STEMCCA vector has been achieved by 
transfection of a Cre-IRES-Puro plasmid to obtain hiPSCs 
free of exogenous transgenes (Somers A et al., in press). 
Th  ese approaches, however, do not completely eliminate 
the theoretical risk of insertional mutagenesis since 
approximately 200 base pairs of exogenous DNA remain in 
the host genome after excision. Th   e fact that the remaining 
sequence is an inactive viral LTR, together with the 
possibility of sequencing the integration site, may improve 
the applicability of these approaches in the clinical arena.
As an alternative to integrating viral vectors, the 
piggyBac (PB) transposon/transposase system has been 
recently adapted for iPSC generation. PB transposons are 
characterized by a high transposition activity in mam-
malian cells and a precise self-excision from genomic loci 
in mouse ESCs [28]. Woltjen and colleagues [29] 
engineered a PB transposon-based multiprotein expres-
sion vector to generate iPSCs carrying a single genomic 
integration. Remarkably, as a result of the transient 
expression of PB transposase, 90% of the clones showed 
no traces of exogenous DNA after excision. Yusa and 
colleagues [30] further optimized the protocol by includ-
ing a negative selection cassette to facilitate the identiﬁ  -
cation of integration-free iPSCs. Th  is method is signiﬁ  -
cantly less eﬃ   cient than lentiviral-mediated reprogram-
ming [31] but is substantially safer. Nevertheless, its 
potential use in a clinical setting will require a thorough 
examination of the iPSC clones to exclude the presence 
of transposon-induced genomic rearrangements [32].
Non-integrating vectors and direct delivery of 
reprogramming proteins
IPSCs result from the overexpression of transcription 
factors over several days during which the endogenous 
factors are activated and maintain the pluripotency gene 
network [33,34]. In principle, transient expression of the 
reprogramming factors from non-integrating vectors 
could provide the level and duration of expression that 
are required to induce pluripotency. A number of studies 
have described the successful derivation of mouse iPSCs 
by using plasmids [35,36] and adenoviral vectors [37], 
providing proof of principle that proviral insertions are 
not necessary for iPSC generation. Most recently, 
expression of reprogramming factors from a non-viral 
minicircle vector proved capable of converting human 
adipose stem cells to pluripotency [38]. Likewise, Fusaki 
and colleagues [39] used RNA Sendai virus-based vectors 
to achieve reprogramming of human somatic cells and 
were able to derive transgene-free hiPSCs by antibody-
mediated negative selection. Alternatively, Th  omson  and 
colleagues [40] employed an oriP/EBNA1 episomal vector 
to reprogram human ﬁ   broblasts. Derived from the 
Epstein-Barr virus, these plasmids replicate extrachromo-
somally but are gradually lost from cells upon removal of 
drug selection. Th   e strategy of these authors entailed the 
introduction of a polycistronic vector encoding the genes 
Oct4, Sox2, Nanog, Lin28, c-Myc, Klf4, and SV40LT and 
selection of stable episomes that provided persistent gene 
expression to achieve reprogramming followed by the 
identiﬁ   cation of vector-free subclones after several 
passages in the absence of selection. As with the other 
non-integrating delivery systems, the reprogramming 
rates were very low (approximately 0.0005%). To date, it 
remains unclear whether these approaches could be 
translated to the clinic given the low eﬃ   ciencies reported. 
In addition, the possibility that vector pieces have 
integrated into the host genome is diﬃ   cult to rule out by 
polymerase chain reaction analysis and this matter may 
require whole-genome sequencing [9].
One possible way to induce pluripotency in somatic 
cells while avoiding the risks of genomic modiﬁ  cations is 
through direct delivery of reprogramming proteins. Such 
a strategy has been reported by diﬀ   erent groups. To 
enable cellular uptake, the reprogramming factors were 
tagged to a poly-arginine protein transduction domain 
and produced in Escherichia coli. As a result of repeated 
incubation of mouse ﬁ  broblasts with the puriﬁ  ed tagged 
proteins and the histone deacetylase inhibitor valproic 
acid (VPA), a few iPSC colonies emerged on days 30 to 35 
[41]. Kim and colleagues [42] recently extended these 
ﬁ  ndings to produce hiPSCs by means of a slightly diﬀ  er-
ent approach, which employed whole-protein extracts 
from HEK293 cells stably expressing the tagged repro-
gram  ming proteins. Finally, a recent report demonstrates 
that a single transfer of ESC-derived proteins is able to 
induce pluripotency in adult mouse ﬁ  broblasts  [43]. 
Although the generation of these so-called protein 
hiPSCs (p-hiPSCs) is quite ineﬃ   cient (about 0.001% of 
input cells) and takes about 8 weeks, the study is proof of 
concept that human somatic cells can be reprogrammed 
by direct protein delivery. Importantly, p-hiPSCs were 
produced in the absence of chemicals such as VPA, which 
may induce mutations [9].
It is widely accepted that the choice of the delivery 
method will impact the reprogramming eﬃ   ciency, which 
is deﬁ   ned as the number of formed colonies divided 
either by the number of cells seeded or, more accurately, 
by the number of cells that were eﬀ  ectively transduced/
transfected with the reprogramming factors [44]. 
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number of colonies that emerge in a typical experiment 
using retro/lentiviruses is low, and most studies have 
reported reprogramming rates of 0.001% to 1%. In fact, 
the evidence indicates that in addition to the delivery 
method, these values will be subject to other sources of 
variation that include the transcription factors and target 
cell type employed, the age of the donor, the passage 
number of the cells (inversely correlated with eﬃ   ciency), 
and whether the speciﬁ  c protocol includes splitting of 
cells after infection/transfection. Th  ese variables hinder 
proper comparisons across the studies, even when similar 
delivery methods are used.
Transcription factor cocktails, donor cells, and 
chemical additives: the various ways to create an 
induced pluripotent stem cell
In their seminal work, Takahashi and Yamanaka [2] 
screened a library of 24 transcription factors for their 
ability to induce pluripotency in somatic cells and 
ultimately selected four (Oct4, Klf4, Sox2, and c-Myc), 
which are commonly referred to as the ‘Yamanaka factors’. 
Exogenous expression of these genes was found to be 
eﬀ  ective also in reprogramming human somatic cells, as 
reported one year later [5]. Concurrently, the Th  omson 
group [6] demonstrated hiPSC derivation by using a 
slightly diﬀ   erent set of transcription factors, namely 
Oct4, Sox2, Nanog, and Lin28. At present, Oct4 is the 
only factor that cannot be replaced by other Oct family 
members [45], and this is consistent with its critical role 
in maintaining pluripotency [46]. A recent report, 
however, indicates that Oct4-independent repro  gram-
ming is possible through overexpression of the orphan 
nuclear receptor Nr5a2 [47], which operates in part by 
activating endogenous Nanog and Oct4. Interest  ingly, 
another orphan nuclear receptor, Esrrb, is capable of 
replacing Klf4 [48]. Moreover, p53 siRNA (short inter-
fering RNA) and UTF1 were found to signiﬁ  cantly 
increase the eﬃ     ciency of iPSCs generated with the 
Yamanaka factors [49]. Not surprisingly, few factors are 
required to impart pluripotency in cell types that already 
express high endogenous levels of a reprogramming 
factor. For example, ﬁ   broblasts can be reprogrammed 
without c-Myc [45] and overexpression of only Oct4 con-
verts neural stem cells into iPSCs [50], albeit at very low 
rates. Together, these studies provide new insights into 
the molecular basis of nuclear reprogramming and 
indicate that diﬀ   erent sets of exogenously introduced 
transcription factors can jump-start the endogenous 
pluripotency gene network. Whether the choice of the 
reprogramming cocktail contributes to the variability 
observed across iPSC lines deserves further investigation.
Nuclear reprogramming to pluripotency is a gradual 
process that involves the conversion of the epigenetic 
state of a diﬀ  erentiated cell into that of an ESC-like cell 
[1]. To date, iPSCs have been produced from several 
types of somatic cells, including embryonic and adult 
ﬁ  broblasts [2], keratinocytes [8], neural stem cells [51], 
hepato  cytes and gastric epithelial cells [52], B lympho-
cytes [53], and peripheral blood cells [54]. However, as 
each mammalian cell type is characterized by a distinct 
epigenome, some of them appear to be more amenable to 
reprogramming. Th   us, mouse embryonic ﬁ  broblasts 
repro  gram more rapidly and eﬃ   ciently  than  adult 
ﬁ  broblasts [55], and reprogramming is faster in mouse 
stomach and liver cells compared with ﬁ  broblasts [52]. 
Similarly, reprogramming appears to be at least 100-fold 
more eﬃ   cient in human keratinocytes than in ﬁ  broblasts 
[8], although this has not been reproduced by others yet 
[19]. Th  e use of ‘reprogrammable’ mouse strains could 
provide further insight into the reprogrammability of 
diﬀ  erent specialized cell types [56]. In fact, a secondary 
system for the inducible expression of the reprogramming 
factors was recently employed to analyze the impact of 
the diﬀ  erentiation status of the cell on reprogramming. 
By examining the reprogrammability of hematopoietic 
cells at diﬀ   erent stages of development, Eminli and 
colleagues [57] demonstrated that immature blood cells 
reprogram more eﬃ     ciently than their diﬀ  erentiated 
progeny. Th  ese analyses may assist in the selection of 
suitable targets for the eﬃ   cient generation of iPSCs.
Alternatively, small molecules that enhance reprogram-
ming eﬃ   ciency or even substitute for a reprogramming 
factor have been identiﬁ  ed. Some of these compounds 
induce epigenetic changes by inhibiting the activity of 
chromatin remodeling factors. In the presence of the 
DNA methyltransferase inhibitor 5΄-azacytidine (5΄-azaC) 
or the histone deacetylase inhibitor VPA, the eﬃ   ciency of 
reprogramming can be enhanced by approximately 
10-fold and 100-fold, respectively [58]. Furthermore, 
VPA is able to compensate for c-Myc and Klf4 during 
conversion of human ﬁ  broblasts to iPSCs [59]. Likewise, 
the G9a histone methyltransferase inhibitor BIX-01294, 
together with BayK8644, an L-type calcium channel 
agonist, allows reprogramming of mouse embryonic 
ﬁ   broblasts transduced with Oct4 and Klf4 only [60]. 
Among the compounds that target signal transduction 
pathways, inhibitors of transforming growth factor-beta 
signaling have been shown to increase reprogramming 
eﬃ     ciency and substitute for Sox2 and c-Myc [61,62]. 
Also, the kinase inhibitor kenpaullone was found to 
replace Klf4 [63], although the underlying mechanism is 
unknown at present. Finally, a recent report demonstrates 
that vitamin C improves the generation of mouse iPSCs 
and hiPSCs [64], in part by alleviating cell senescence 
through p53 repression and probably by acting as an 
agonist of the hypoxia-inducible factor pathway. Th  ese 
results are in agreement with the recent ﬁ  nding  that 
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Of note, many of these molecules have pleiotropic eﬀ  ects 
that could result in transient or permanent epigenetic or 
genetic alterations, hindering the use of chemically 
induced iPSCs for therapeutic purposes.
Conclusions
Reprogramming with deﬁ   ned transcription factors 
provides a simple way of producing customized pluri-
potent stem cells with enormous therapeutic potential. 
Although viral transduction of the Yamanaka factors 
remains the most common strategy for producing iPSCs, 
signiﬁ   cant progress has been made in improving the 
eﬃ   ciency and safety of the technique. Excisable vectors 
may prove suitable for most applications, and methods 
that rely on non-integrative vectors or protein delivery 
might become routine once their eﬃ   ciency is enhanced. 
Th  e use of high-throughput screening technologies to 
identify small molecules that modulate the expression 
and/or activity of regulators of pluripotency in somatic 
cells could potentially allow reprogramming by purely 
chemical means. Whether the choice of the donor cell 
and reprogramming method eventually have an eﬀ  ect on 
the ability of iPSCs to diﬀ  erentiate into functional cell 
types will require additional investigation. Given the 
rapid pace of the ﬁ   eld, further optimization of the 
protocols coupled with a thorough analysis of the iPSC 
lines generated will facilitate the clinical translation of 
this technology.
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